SEC
SlamSEC
SearchBrowseEarnings

Atai Beckley N.V.

Nasdaq:ATAI
Pharmaceutical Preparations·AMSTELVEEN
OverviewAll FilingsSum FinCreditInsidersGovernance
OverviewAll FilingsSum FinCreditInsidersGovernance

Summary Financials

atai Life Sciences is a pharmaceutical company that is developing psychedelics, other hallucinogens, entactogens, and related drugs for treatment of psychiatric conditions. It was founded in 2018 and is headquartered in Berlin, Germany.

Revenue
$314,000
+34.8% YoY
FY 2024
Adj. EBITDA
-$125.2M
-39857.3% margin
FY 2024
Net Income
-$40.2M
-12810.2% margin
FY 2024
EPS (Diluted)
-$0.25
FY 2024
Stock Price
$4.14
+6.2%
2026-03-10
52W Range
$1.15 – $6.75
P/E Ratio
-16.6x
Market Cap
$1.5B
Cash
$45.0M
FY 2024
Total Debt
$59.8M
FY 2024
Net Debt
$14.8M
FY 2024
Enterprise Value
$1.5B
Debt / EBITDA
-0.1x
FY 2024
EV / EBITDA
-12.1x
Employees
—